Final Professional MBBS — Ophthalmology (complete, 12 chapters). Explanation-first answers with anatomical, optics, neuro & public-health diagrams, classifications, comparison tables, drug doses, clinical pearls and key-point recaps from Khurana's Comprehensive Ophthalmology, Parsons' Diseases of the Eye and Park's PSM.
12chapters144questions39High-Yield
THE CONCEPT
Blindness is a major global public-health problem, and its most important feature is that most of it is avoidable. Community ophthalmology exists to reduce this avoidable blindness through prevention and treatment at the population level, rather than one patient at a time.
Leading causes of blindness (approx.)
Cataract~50%
Refractive error~20%
Glaucoma~8%
ARMD~5%
Corneal opacity~4%
Diabetic retinopathy~3%
Trachoma~2%
Cataract is the single leading cause; ~80% of all blindness is avoidable
The leading causes of blindness: cataract is by far the single largest, followed by uncorrected refractive error, glaucoma, ARMD, corneal opacity, diabetic retinopathy and trachoma. Around 80% of all blindness is avoidable.
DEFINITION (WHO)
The WHO defines visual impairment and blindness by the visual acuity and visual field in the better eye. Categories run from mild, moderate and severe visual impairment to blindness, and blindness is defined as a presenting visual acuity of less than 3/60 in the better eye, or a visual field of less than 10°. (India's national programme historically used a broader definition of <6/60, now being harmonised with the WHO <3/60 standard.)
MAGNITUDE
There are of the order of 40 million or more blind people worldwide, the large majority in developing countries, and — crucially — around 80% of this blindness is avoidable (either preventable or treatable).
CAUSES
In global order, the leading causes are cataract (the single commonest, roughly half), uncorrected refractive error, glaucoma, age-related macular degeneration, corneal opacity, diabetic retinopathy, trachoma and childhood blindness (including vitamin A deficiency). In India, cataract is the leading cause, followed by uncorrected refractive error. Avoidable blindness comprises the preventable causes (trachoma, vitamin A deficiency, ophthalmia neonatorum) and the treatable/curable causes (cataract, refractive error, glaucoma).
💡
CLINICAL PEARL: Blindness (WHO) = a presenting visual acuity of <3/60 in the better eye (or a field <10°). There are ~40 million blind worldwide, ~80% avoidable (preventable + treatable). The leading causes are cataract (commonest), uncorrected refractive error, glaucoma, ARMD, corneal opacity, diabetic retinopathy and trachoma. Community ophthalmology targets this avoidable blindness.
WHY 'AVOIDABLE' IS THE KEY WORD
The single most important idea in community ophthalmology is that around 80% of the world's blindness is 'avoidable' — and understanding this term reshapes the whole approach. 'Avoidable' blindness is that which could be prevented, or which can be treated to restore sight, and it splits into two groups: the preventable causes (such as trachoma, vitamin A deficiency and ophthalmia neonatorum), which never need to occur if the right public-health measures are in place, and the treatable/curable causes (such as cataract and uncorrected refractive error), where sight can be fully restored by a simple operation or a pair of glasses. The implication is powerful: the majority of blind people need not be blind, so the emphasis shifts from high-technology cures to organised, population-level delivery of a few, largely simple, interventions — which is exactly what programmes like VISION 2020 are built to do.
THE PATTERN IN DEVELOPING COUNTRIES
It is important to appreciate how the pattern of blindness differs between rich and poor countries, because it drives priorities. In developing countries — where most of the world's blind live — the leading causes are overwhelmingly the avoidable ones: cataract, uncorrected refractive error, and infections/nutritional deficiencies such as trachoma and vitamin A deficiency. In high-income countries, by contrast, the leading causes are the more intractable age-related and degenerative diseases — ARMD, glaucoma and diabetic retinopathy. This difference explains why blindness-control programmes in countries like India concentrate first on clearing the cataract backlog and correcting refractive error (huge, quickly-treatable causes), while also building capacity for the growing burden of diabetic and glaucomatous blindness that accompanies development and ageing.
THE BOTTOM LINE
Blindness is a large, largely avoidable global burden concentrated in poor countries, led everywhere by cataract and uncorrected refractive error; recognising that around 80% is preventable or treatable is what makes population-level control both possible and urgent.
A NOTE ON MEASURING BLINDNESS
It is useful to understand that blindness is defined and measured by a standard, acuity-and-field-based classification precisely so that populations can be compared and programmes evaluated. Using the better eye and a specified cut-off (WHO: presenting VA <3/60, or a field <10°) gives an objective, reproducible measure of the burden, and the distinction between 'presenting' and 'best-corrected' vision matters — counting presenting vision captures the large amount of impairment due simply to uncorrected refractive error, which a best-corrected definition would miss. Standardised definitions therefore underpin the whole discipline: they let us estimate how many people are blind, identify the causes, set targets and measure whether interventions are working.
💊
KEY POINTS / NUMBERS (viva)
WHO blindness = presenting VA <3/60 in the better eye, or visual field <10°; categories — mild/moderate/severe visual impairment, then blindness.
Community ophthalmology tackles avoidable blindness at the population level through prevention and treatment.
📚
SOURCES: Khurana's Comprehensive Ophthalmology (Community Ophthalmology); Park's Textbook of Preventive & Social Medicine.
THE CONCEPT
Vitamin A deficiency (VAD) is the leading cause of preventable childhood blindness worldwide, affecting malnourished young children. Xerophthalmia is the term for the spectrum of ocular signs of VAD. Vitamin A is essential both for the retinal photoreceptors (as a component of rhodopsin) and for maintaining the integrity of the conjunctival and corneal epithelium.
Xerophthalmia — the spectrum of vitamin A deficiency
XNNight blindness
X1A/BXerosis /Bitot's spot
X2Corneal xerosis
X3A/BKeratomalacia(blinding)
XSScar
reversible with vitamin A
irreversible / blinding
Vitamin A: needed for rhodopsin (night vision) & epithelial integrity — treat early with high-dose vitamin A
The xerophthalmia spectrum of vitamin A deficiency, from night blindness (XN, reversible) through conjunctival xerosis and Bitot's spots (X1) and corneal xerosis (X2) to sight-destroying keratomalacia (X3). Early stages reverse with vitamin A; late stages blind.
THE TWO OCULAR ROLES OF VITAMIN A
Retinal — vitamin A is part of rhodopsin, the rod pigment for night (scotopic) vision; its deficiency causes night blindness.
Epithelial — vitamin A maintains non-keratinised, mucin-producing (goblet-cell) epithelium; its deficiency causes xerosis (drying and keratinisation) of the conjunctiva and cornea.
WHO CLASSIFICATION OF XEROPHTHALMIA
XN — night blindness (the earliest sign, from rod dysfunction).
X1A — conjunctival xerosis; X1B — Bitot's spot (a foamy triangular patch on the temporal conjunctiva).
A crucial clinical point is the deadly synergy between vitamin A deficiency, measles and malnutrition. A child with borderline vitamin A status can be tipped into acute, blinding xerophthalmia by an intercurrent illness — especially measles, diarrhoea or protein-energy malnutrition — which depletes vitamin A stores, reduces intake and increases demand all at once. This is why keratomalacia so often follows measles in a malnourished child, and why the WHO recommends giving vitamin A to all children with measles in deficient areas. It also explains why vitamin A deficiency is not just an eye problem: the same deficiency increases the severity of infections and raises overall child mortality, so vitamin A supplementation improves child survival as well as protecting sight — a double benefit that underpins its place in child-health programmes.
PROPHYLAXIS AS A PUBLIC-HEALTH TRIUMPH
The vitamin A prophylaxis programme is worth highlighting as a model of cheap, effective public-health prevention. Because the eye disease is entirely preventable and the supplement is inexpensive, safe and needed only intermittently, a simple schedule of periodic high-dose vitamin A (in India, linked to measles vaccination at 9 months and then given six-monthly to the age of five) can virtually abolish nutritional blindness in a population. Combined with promotion of vitamin-A-rich foods (green leafy vegetables, yellow fruits), breastfeeding, and measles immunisation, it addresses the deficiency at primordial, primary and secondary levels at once. The success of such programmes is why nutritional blindness has fallen dramatically where they are implemented — and why lapses in coverage quickly allow xerophthalmia to reappear.
⚠️
DANGER / REMEMBER: Treat with high-dose vitamin A: 200,000 IU orally on day 1, day 2 and day 14 (halved for infants 6–12 months, quartered for <6 months), together with treatment of measles/infection/malnutrition and corneal protection in keratomalacia.
Prevention is by universal high-dose vitamin A prophylaxis (in India, 100,000 IU at 9 months with measles vaccination, then 200,000 IU every 6 months up to 5 years), a diet rich in green leafy vegetables, yellow fruits and liver, breastfeeding, and measles control.
💡
CLINICAL PEARL: Vitamin A deficiency is the leading cause of preventable childhood blindness. The xerophthalmia spectrum runs XN night blindness (earliest) → X1B Bitot's spot → X2 corneal xerosis → X3 keratomalacia (blinding). Vitamin A is needed for rhodopsin (night vision) and epithelial integrity. Treat with high-dose vitamin A (200,000 IU on days 1, 2 and 14); prevent with prophylaxis (9 months, then 6-monthly to 5 years), diet and measles control.
💊
KEY POINTS / NUMBERS (viva)
VAD = leading cause of preventable childhood blindness; vitamin A needed for rhodopsin (night vision) + epithelial integrity.
Treat: vitamin A 200,000 IU orally day 1, day 2, day 14 (100,000 for 6–12 mo, 50,000 for <6 mo) + treat measles/infection/malnutrition. Prevent (India): 100,000 IU at 9 mo (with measles), then 200,000 IU 6-monthly to 5 y + diet.
🔑
KEY POINTS TO REMEMBER
Vitamin A deficiency = leading cause of preventable childhood blindness; xerophthalmia = its ocular spectrum.
Vitamin A roles: rhodopsin (rod pigment for night vision) and epithelial integrity (goblet cells/mucin).
Treat: vitamin A 200,000 IU on days 1, 2 and 14 (reduced for infants) + treat measles/infection/malnutrition + protect cornea.
Prevent: prophylaxis (India — 9 months with measles, then 6-monthly to 5 years), vitamin-A-rich diet, breastfeeding, measles control.
📚
SOURCES: Khurana's Comprehensive Ophthalmology; Park's Textbook of Preventive & Social Medicine.
THE CONCEPT
Trachoma is a chronic keratoconjunctivitis caused by Chlamydia trachomatis (serotypes A, B, Ba, C) and is the leading infectious cause of blindness worldwide. It is a disease of poverty — poor hygiene, overcrowding and lack of water/sanitation — and spreads by eye-to-eye contact, fomites (shared towels) and flies.
Trachoma cycle & the SAFE strategy
Repeated Chlamydiainfection (flies, hygiene)
Active trachomafollicles (TF/TI)
Conjunctivalscarring (TS)
Trichiasis /entropion (TT)
Corneal opacity→ blindness (CO)
SAFE
S – SurgeryA – Antibiotics(azithromycin)F – FacialcleanlinessE – Environment
The trachoma cycle — repeated chlamydial infection → active follicular disease → conjunctival scarring → trichiasis/entropion → corneal opacity and blindness — and the WHO SAFE strategy that breaks it: Surgery, Antibiotics, Facial cleanliness and Environmental improvement.
PATHOGENESIS
Repeated infection causes a chronic follicular conjunctivitis, which over years leads to conjunctival scarring → entropion and trichiasis → the in-turned lashes abrade the cornea → corneal opacity → blindness. It is the repeated re-infection, not a single episode, that drives this blinding sequence.
GRADING (WHO simplified) & SIGNS
TF — Trachomatous inflammation, Follicular (≥5 follicles on the upper tarsal conjunctiva).
Signs: follicles on the upper tarsus, papillae, pannus (superior corneal vascularisation), Herbert's pits (scarred limbal follicles — pathognomonic) and Arlt's line (a linear tarsal scar).
CONTROL — THE SAFE STRATEGY
The WHO strategy for eliminating blinding trachoma is SAFE: S — Surgery for trichiasis (bilamellar tarsal rotation); A — Antibiotics (a single oral dose of azithromycin, given as mass drug administration, or tetracycline eye ointment); F — Facial cleanliness (to reduce transmission); and E — Environmental improvement (water, sanitation and fly control).
💡
CLINICAL PEARL: Trachoma is a chronic Chlamydia trachomatis keratoconjunctivitis — the leading infectious cause of blindness and a disease of poverty (flies, poor hygiene). Repeated infection → follicles → scarring (Arlt's line) → trichiasis/entropion → corneal opacity → blindness. Signs include follicles, pannus and Herbert's pits (pathognomonic). Control is by the SAFE strategy — Surgery, Antibiotics (azithromycin), Facial cleanliness and Environmental improvement.
WHY REPEATED INFECTION IS THE KEY
The concept that makes trachoma understandable is that blindness results from repeated re-infection over many years, not from a single episode. A one-off chlamydial conjunctivitis heals; but in conditions of poverty, crowding and poor hygiene, children are re-infected again and again (from other children, shared cloths and eye-seeking flies), and it is this chronic, repeated inflammation that gradually scars the conjunctiva. The scarring slowly contracts over decades, turning the lid inward (entropion) so the lashes rub the cornea (trichiasis), and the constant abrasion finally opacifies the cornea. This long, cumulative natural history explains why trachoma is a disease of communities rather than individuals, why it blinds adults (usually women, who care for infected children) from infections acquired in childhood, and why control must interrupt transmission across a whole population — the logic behind the SAFE strategy.
HOW SAFE BREAKS THE CYCLE
The elegance of the SAFE strategy is that each component targets a different point in the disease cycle, combining immediate treatment with long-term prevention. Surgery corrects the trichiasis that is actively destroying the cornea now, preventing blindness in those already scarred. Antibiotics (a single annual oral dose of azithromycin, given to whole communities as mass drug administration) reduce the reservoir of active infection. Facial cleanliness cuts person-to-person and fly-borne transmission, and Environmental improvement (clean water, latrines and fly control) removes the underlying conditions that sustain the disease. Because it works simultaneously on the individual already at risk of blindness and on the community-wide transmission, SAFE has driven trachoma toward elimination in many countries — a leading example of an integrated public-health approach to a blinding disease.
A NOTE ON ELIMINATION AS A GOAL
Trachoma is notable as a disease targeted for elimination as a public-health problem, and understanding why is instructive. Because it is caused by a single, treatable organism, transmitted under identifiable conditions, and controllable by a proven, integrated strategy (SAFE), blinding trachoma can realistically be eliminated from whole districts and countries — and many have already achieved this. Progress is measured against defined targets (reducing the prevalence of active disease TF in children and of trichiasis TT to set thresholds). This makes trachoma a flagship of the VISION 2020 approach and a demonstration that a formerly major cause of global blindness can be driven toward disappearance by sustained, community-wide public-health action rather than by treating individuals alone.
💊
KEY POINTS / NUMBERS (viva)
Trachoma = chronic Chlamydia trachomatis (A, B, Ba, C) keratoconjunctivitis; leading infectious cause of blindness; spread by contact/fomites/flies (poverty).
Signs: follicles (upper tarsus), pannus, Herbert's pits (pathognomonic), Arlt's line. Control = SAFE (Surgery for trichiasis, Antibiotics — azithromycin single dose/tetracycline, Facial cleanliness, Environmental improvement).
🔑
KEY POINTS TO REMEMBER
Trachoma = chronic keratoconjunctivitis from Chlamydia trachomatis; leading infectious cause of blindness; disease of poverty (flies, poor hygiene, overcrowding).
Control = SAFE strategy: Surgery (trichiasis), Antibiotics (azithromycin/tetracycline), Facial cleanliness, Environmental improvement.
📚
SOURCES: Khurana's Comprehensive Ophthalmology; Park's Textbook of Preventive & Social Medicine.
THE CONCEPT
Cataract is the leading cause of blindness worldwide and in India — but, unlike most causes, it is completely curable by surgery. The public-health challenge is therefore not the treatment itself but delivering high-volume, high-quality, affordable cataract surgery to clear the huge accumulated 'backlog' of blind people awaiting it.
~80%
avoidable
Avoidable (~80%)
= preventable + treatable
Not avoidable (~20%)
Preventable (trachoma, vitamin A, ophthalmia neonatorum) + treatable (cataract, refractive error)
About 80% of the world's blindness is avoidable — either preventable (trachoma, vitamin A deficiency, ophthalmia neonatorum) or treatable (cataract, refractive error) — which is the entire rationale for community-ophthalmology programmes.
MAGNITUDE & KEY CONCEPTS
Cataract accounts for roughly half of blindness in India, with a large backlog of unoperated cases (in some areas the new cases each year still exceed the number operated).
Cataract Surgical Rate (CSR) — the number of cataract operations performed per million population per year — measures how well services are delivering.
Cataract Surgical Coverage — the proportion of those needing surgery who have actually received it.
BARRIERS TO UPTAKE
Even where surgery is available, uptake is limited by cost, distance/access, lack of awareness, fear of surgery, poorer access for women, and concerns about the quality of outcomes.
STRATEGY FOR CONTROL
Cataract blindness is controlled by high-volume, high-quality surgery with intraocular lens implantation (modern small-incision cataract surgery or phacoemulsification with a posterior-chamber IOL — far better than the old intracapsular surgery with thick aphakic glasses); a mix of outreach eye camps/screening and fixed surgical facilities; affordable or free surgery (supported by the national programme); trained personnel; quality monitoring; and active measures to overcome barriers and generate demand.
💡
CLINICAL PEARL: Cataract is the leading, curable cause of blindness in India (~half); the challenge is the backlog. Services are measured by the Cataract Surgical Rate (operations per million per year) and surgical coverage. Control it with high-volume, high-quality surgery with an IOL (SICS/phaco + posterior-chamber IOL), outreach/camps plus fixed facilities, affordable/free surgery, and by tackling barriers (cost, access, awareness, fear, quality).
WHY IOL SURGERY TRANSFORMED CATARACT CONTROL
A key advance worth understanding is why the shift to intraocular-lens (IOL) surgery was so important for controlling cataract blindness. The old intracapsular operation left the eye aphakic, and the patient dependent on thick, high-plus 'cataract glasses' with all their optical penalties — magnification, distortion, a restricted field and a ring scotoma — giving poor, unpopular results that discouraged others from coming forward. Modern small-incision cataract surgery or phacoemulsification with a posterior-chamber IOL restores near-normal, immediately usable vision through a small, quick, sutureless operation. Because good visual outcomes both rehabilitate the individual and generate demand in the community (satisfied patients bring their neighbours), high-quality IOL surgery is central not only to treating cataract but to overcoming the fear and mistrust that keep the backlog unoperated.
A further practical point is that quality is as important as quantity in cataract programmes: a high surgical rate achieved with poor outcomes (from inadequate technique, poor case selection or lack of follow-up) can damage a programme's reputation and depress demand. This is why modern services emphasise monitoring visual outcomes and complication rates alongside the number of operations, ensuring that clearing the backlog also delivers the good vision that sustains community confidence in cataract surgery.
THE BOTTOM LINE
Cataract is the leading but wholly curable cause of blindness, so its control is a delivery problem: clearing the backlog through high-volume, high-quality IOL surgery, measured by the cataract surgical rate and coverage, made affordable and accessible, and matched by demand generated through good visual outcomes.
💊
KEY POINTS / NUMBERS (viva)
Cataract = leading, CURABLE cause of blindness in India (~50%); challenge = clearing the backlog.
Cataract Surgical Rate (CSR) = operations per million population per year; Cataract Surgical Coverage = % of those needing surgery who received it.
Control: high-volume, high-quality surgery with IOL (SICS/phaco + PCIOL, not old aphakic glasses); eye camps/outreach + fixed facilities; affordable/free surgery (NPCB); trained staff; quality monitoring; overcome barriers (cost, distance, awareness, fear, gender, quality).
🔑
KEY POINTS TO REMEMBER
Cataract is the leading cause of blindness worldwide and in India (~half), but is curable by surgery.
Main challenge: the large backlog of unoperated blind people; sometimes new cases exceed the surgical output.
Cataract Surgical Rate (CSR) = operations per million population per year; surgical coverage = proportion of those needing surgery who received it.
Barriers to uptake: cost, distance/access, lack of awareness, fear, poorer access for women, quality concerns.
Control: high-volume, high-quality surgery with IOL (SICS/phaco + PCIOL), outreach camps + fixed facilities, affordable/free surgery, quality monitoring, demand generation.
📚
SOURCES: Khurana's Comprehensive Ophthalmology; Park's Textbook of Preventive & Social Medicine.
THE CONCEPT
Reducing avoidable blindness requires a public-health approach delivered through organised national and global programmes. In India this is the National Programme for Control of Blindness (NPCB), aligned with the global initiative VISION 2020: The Right to Sight.
~80%
avoidable
Avoidable (~80%)
= preventable + treatable
Not avoidable (~20%)
Preventable (trachoma, vitamin A, ophthalmia neonatorum) + treatable (cataract, refractive error)
About 80% of the world's blindness is avoidable — either preventable (trachoma, vitamin A deficiency, ophthalmia neonatorum) or treatable (cataract, refractive error) — which is the entire rationale for community-ophthalmology programmes.
NATIONAL PROGRAMME FOR CONTROL OF BLINDNESS (NPCB)
Launched in 1976 (the first 100% centrally-funded national blindness programme in the world), its aim is to reduce the prevalence of blindness (target around 0.3%). Its activities include cataract surgery with IOL (the main thrust), correction of refractive errors (school eye screening and free spectacles), eye banking for corneal blindness, treatment of glaucoma and diabetic retinopathy, vitamin A prophylaxis (with the child-health programme), trachoma control, public awareness (IEC), infrastructure development (eye hospitals, district units) and training.
VISION 2020: THE RIGHT TO SIGHT
A global initiative of the WHO and the International Agency for the Prevention of Blindness (IAPB), launched in 1999 to eliminate avoidable blindness. It works through three components: (1) control of priority diseases, (2) human-resource development (training), and (3) infrastructure and appropriate technology. Its priority (target) diseases are cataract, refractive errors and low vision, childhood blindness (including vitamin A deficiency), trachoma, onchocerciasis, glaucoma and diabetic retinopathy.
LEVELS OF PREVENTION
The programme applies all levels of prevention: primordial/primary (nutrition, hygiene, vitamin A, immunisation), secondary (early detection and treatment — cataract surgery, glaucoma screening) and tertiary (rehabilitation and low-vision services).
💡
CLINICAL PEARL: Blindness is prevented through NPCB (India, 1976 — cataract surgery/IOL as the main thrust, refractive-error correction/school screening, eye banking, vitamin A, trachoma control) and VISION 2020 'The Right to Sight' (WHO + IAPB, to eliminate avoidable blindness; three pillars — disease control, human resources, infrastructure). The priority diseases are cataract, refractive error, childhood blindness/vitamin A, trachoma, onchocerciasis, glaucoma and diabetic retinopathy.
A NOTE ON PRIMARY EYE CARE & INTEGRATION
A defining feature of modern blindness-control programmes is their emphasis on integrating eye care into the general (primary) health-care system rather than treating it as a separate specialty. Because the priority conditions are common and largely simple, much can be delivered at the primary level — vision screening, refractive-error correction, vitamin A, health education and the identification and referral of cataract, glaucoma and diabetic retinopathy — by trained primary-care and mid-level workers, supported by a referral pyramid up to secondary and tertiary eye-care centres. This integrated, tiered approach (a core principle of both NPCB and VISION 2020) allows scarce ophthalmologists to concentrate on surgery and complex care, extends services to underserved rural populations, and makes the control of avoidable blindness sustainable within the wider public-health system.
Finally, it is worth noting that the burden is shifting: as programmes succeed against cataract and infectious/nutritional causes, and as populations age and diabetes becomes commoner, the chronic non-communicable causes — diabetic retinopathy and glaucoma — are becoming relatively more important. Modern blindness-control strategy therefore increasingly incorporates screening for diabetic retinopathy and glaucoma and the management of these lifelong conditions, alongside the traditional priorities, so that the programmes remain matched to the evolving pattern of avoidable blindness.
THE BOTTOM LINE
Avoidable blindness is tackled through organised programmes — India's NPCB and the global VISION 2020 'Right to Sight' — that combine control of a defined set of priority diseases with the training and infrastructure to deliver eye care, increasingly integrated into primary health care and adapting to the rising burden of diabetic and glaucomatous blindness.
💊
KEY POINTS / NUMBERS (viva)
NPCB (India): launched 1976, first 100% centrally-funded national blindness programme; aim to reduce blindness prevalence (~0.3% target).
VISION 2020 'The Right to Sight' (WHO + IAPB, 1999): eliminate avoidable blindness through 3 pillars — disease control, human resources, infrastructure/technology.
SOURCES: Khurana's Comprehensive Ophthalmology; Park's Textbook of Preventive & Social Medicine.
THE CONCEPT
Night blindness (nyctalopia) is difficulty seeing in dim light or at night, resulting from impaired function of the rod photoreceptors (which mediate vision in low light). It is a symptom, not a diagnosis, and its causes range from readily reversible to progressive and inherited.
CAUSES
Vitamin A deficiency — the commonest cause worldwide and the earliest sign of xerophthalmia (XN); it is treatable and reversible.
Retinitis pigmentosa — an inherited rod–cone dystrophy (progressive).
Congenital stationary night blindness; and secondary causes such as advanced glaucoma, pathological myopia, gyrate atrophy and after pan-retinal photocoagulation.
ASSESSMENT & MANAGEMENT
Assessment includes the history, dark-adaptation testing, ERG, fundus examination and vitamin A status. Management is to treat the cause — vitamin A for deficiency (rapidly reversible) and supportive care for retinitis pigmentosa. The key clinical distinction is between the reversible (vitamin A deficiency) and the progressive/inherited (retinitis pigmentosa) causes.
A NOTE ON THE KEY DISTINCTION
The most useful clinical judgement in a patient with night blindness is separating the rapidly reversible from the progressive causes. Vitamin A deficiency — common, nutritional and treatable — responds within days to vitamin A, so recognising it (often alongside conjunctival xerosis, Bitot's spots and a malnourished child) can restore night vision quickly and prevent the child progressing to blinding keratomalacia. Retinitis pigmentosa, by contrast, is inherited and progressive, with its characteristic fundus triad and a reduced/extinguished ERG, and cannot be cured — only supported. Making this distinction early therefore changes everything: one is a nutritional emergency with a simple cure, the other a genetic condition needing counselling and low-vision care.
THE BOTTOM LINE
Night blindness reflects impaired rod function, most often from treatable vitamin A deficiency (the earliest sign of xerophthalmia) but also from progressive inherited disease like retinitis pigmentosa — and telling these apart is the key clinical step.
A practical corollary is that, in a community where night blindness is common among young children, it should be regarded as a marker of population-level vitamin A deficiency and prompt public-health supplementation, not merely individual treatment; conversely, night blindness appearing in an adult with a normal diet points instead toward a retinal or inherited cause needing ERG and fundus assessment.
🔑
KEY POINTS TO REMEMBER
Night blindness (nyctalopia) = poor vision in dim light from impaired rod function.
Commonest cause: vitamin A deficiency (earliest sign of xerophthalmia, XN — reversible with vitamin A).
Also retinitis pigmentosa (inherited, progressive), congenital stationary night blindness, advanced glaucoma, pathological myopia, post-PRP.
Assess with history, dark adaptation, ERG, fundus, vitamin A status; treat the cause; distinguish reversible (VAD) from progressive (RP).
📚
SOURCES: Khurana's Comprehensive Ophthalmology.
THE CONCEPT
A Bitot's spot is a sign of vitamin A deficiency (xerophthalmia stage X1B). It is a foamy or cheesy, greyish-white, triangular patch on the bulbar conjunctiva, characteristically on the temporal (lateral) side near the limbus, within the interpalpebral zone, and is usually bilateral.
Bitot's spot: foamy triangular patch on the temporal conjunctiva
A Bitot's spot: a foamy, greyish-white, triangular patch of keratinised conjunctiva on the temporal bulbar conjunctiva — a sign of vitamin A deficiency (xerophthalmia stage X1B).
NATURE & ASSOCIATIONS
It consists of keratinised, desquamated conjunctival epithelium, often with foam produced by Corynebacterium xerosis growing on the dry surface. It is typically accompanied by conjunctival xerosis and night blindness, and is seen mainly in malnourished children.
SIGNIFICANCE & MANAGEMENT
A Bitot's spot is an important warning marker of vitamin A deficiency requiring vitamin A therapy. Note that the foamy patch itself may persist even after treatment (the keratinisation does not always fully reverse), so it is the deficiency, not the spot, that is treated — with high-dose vitamin A and dietary improvement.
A NOTE ON ITS PUBLIC-HEALTH VALUE
Beyond the individual child, the Bitot's spot has real public-health value as an easily-recognised field sign of vitamin A deficiency in a community. Because it can be identified on simple inspection without equipment, the prevalence of Bitot's spots (and of night blindness) among pre-school children is used by the WHO as an indicator of whether vitamin A deficiency is a public-health problem in an area, triggering supplementation programmes. So finding Bitot's spots should prompt not only treating the child in front of you but considering the nutritional status of the whole community — a good illustration of how a single clinical sign links individual care to population-level action.
THE BOTTOM LINE
A Bitot's spot is a foamy triangular conjunctival patch signalling vitamin A deficiency, useful both as a prompt to treat the child and as a community indicator of nutritional blindness.
It is also worth noting that the classic temporal, interpalpebral location of a Bitot's spot reflects the area of conjunctiva most exposed to drying between the lids, and that its foamy appearance comes partly from gas-producing commensal bacteria colonising the abnormally keratinised surface — details that help distinguish a true Bitot's spot from other conjunctival lesions when making the diagnosis of vitamin A deficiency.
🔑
KEY POINTS TO REMEMBER
Bitot's spot = sign of vitamin A deficiency (xerophthalmia X1B).
Foamy/cheesy, greyish-white, triangular patch on the temporal bulbar conjunctiva (interpalpebral), usually bilateral.
Keratinised conjunctival epithelium + foam (Corynebacterium xerosis); with conjunctival xerosis and night blindness, mainly in malnourished children.
A marker needing high-dose vitamin A + diet; the spot itself may persist after treatment (treat the deficiency, not the spot).
📚
SOURCES: Khurana's Comprehensive Ophthalmology.
THE CONCEPT
Keratomalacia is the most severe, blinding stage of xerophthalmia (X3) — a rapid softening and liquefactive necrosis ('melting') of the cornea due to severe vitamin A deficiency, usually in a malnourished, infected young child. It is an ophthalmic emergency.
FEATURES
The cornea becomes hazy and then undergoes colliquative necrosis, which may perforate, leading to a staphyloma or phthisis bulbi and blindness. It is often bilateral and characteristically painless (from associated corneal anaesthesia), and is frequently precipitated by measles, diarrhoea or protein-energy malnutrition.
MANAGEMENT
A NOTE ON PREVENTION OVER CURE
The overriding lesson of keratomalacia is that it represents a failure of prevention — by the time the cornea is melting, much of the eye may already be lost despite treatment. This is why the emphasis in community ophthalmology is so heavily on the earlier, reversible stages and on prophylaxis: a child recognised at the stage of night blindness or Bitot's spots can be fully cured with vitamin A, whereas one presenting with keratomalacia often ends up blind in the affected eye. Keratomalacia therefore stands as a stark argument for vitamin A supplementation programmes, measles immunisation and early recognition of xerophthalmia — preventing a tragedy that is entirely avoidable and, once advanced, largely untreatable.
THE BOTTOM LINE
Keratomalacia is the blinding end-stage of vitamin A deficiency — a melting cornea in a malnourished, often measles-affected child — that is an emergency to treat but far better prevented by vitamin A prophylaxis.
For completeness, keratomalacia is frequently bilateral and remarkably painless despite the dramatic corneal destruction, because vitamin A deficiency also reduces corneal sensation; this lack of pain means the condition can advance unnoticed by carers, which is another reason why active screening of at-risk malnourished children, rather than waiting for symptoms, is so important.
⚠️
DANGER / REMEMBER: Management is immediate high-dose vitamin A (the 200,000 IU day 1/2/14 regimen), treatment of the underlying infection and malnutrition, and corneal protection (antibiotics, lubricants, a pad/shield), with management of any perforation. It is entirely preventable by vitamin A prophylaxis, and its existence underlines the importance of treating vitamin A deficiency early, before this stage is reached.
🔑
KEY POINTS TO REMEMBER
Keratomalacia = most severe, blinding stage of xerophthalmia (X3): rapid liquefactive necrosis ('melting') of the cornea from severe VAD.
Malnourished/infected young child; often bilateral and painless; may perforate → staphyloma/phthisis → blindness; precipitated by measles/diarrhoea/PEM.
An ophthalmic emergency: immediate high-dose vitamin A (200,000 IU day 1/2/14) + treat infection/malnutrition + protect cornea.
Preventable by vitamin A prophylaxis; emphasises early treatment of VAD.
📚
SOURCES: Khurana's Comprehensive Ophthalmology.
THE CONCEPT
Corneal opacity/scarring is a major cause of avoidable blindness that is treatable by corneal transplantation (keratoplasty), using donor corneas supplied by eye banks. An eye bank collects, evaluates, stores and distributes donor eyes/corneas.
THE PROCESS
Corneas are retrieved from deceased donors within hours of death, screened to exclude transmissible disease (HIV, hepatitis, rabies, septicaemia and certain other conditions), and stored in preservation media (McCarey–Kaufman or organ-culture). Because the cornea is avascular and immune-privileged, corneal grafts have a relatively high success rate.
KERATOPLASTY & PROMOTION
Keratoplasty may be penetrating (full-thickness) or lamellar (partial-thickness — DALK for anterior disease, DSEK/DMEK for endothelial disease). A major challenge is the shortage of donor corneas, addressed by promoting eye donation (pledging) and hospital cornea-retrieval programmes. Eye banking is part of the national blindness-control programme.
A NOTE ON THE DONOR SHORTAGE
The principal limitation on treating corneal blindness is not surgical skill but the shortage of donor corneas, which is why promotion of eye donation is a central public-health activity. Since a corneal graft can restore sight to a person blind from corneal scarring — and the cornea can be donated by almost anyone after death, regardless of age or eyesight — raising awareness, encouraging pledging, and running hospital-based cornea-retrieval programmes can substantially increase supply. Overcoming cultural reluctance and organising timely retrieval are therefore as important as the surgery itself, and are built into national programmes so that the large number of people blind from treatable corneal disease can actually receive transplants.
THE BOTTOM LINE
Eye banking supplies donor corneas for keratoplasty, which can cure corneal blindness thanks to the cornea's immune privilege — the main limitation being the donor shortage that eye-donation promotion seeks to overcome.
A useful additional point is that, because the cornea can be donated by almost anyone after death irrespective of age, spectacle use or most eye conditions, the potential donor pool is very large; the practical challenge is timely retrieval and the cultural acceptance of donation, which is why hospital cornea-retrieval programmes and sustained public education are emphasised as much as the surgery itself.
🔑
KEY POINTS TO REMEMBER
Corneal blindness is treatable by keratoplasty using donor corneas from eye banks (collect, evaluate, store, distribute).
Corneas retrieved from deceased donors within hours of death; screened (exclude HIV/hepatitis/rabies/sepsis); stored in MK/organ-culture media.
Cornea is avascular and immune-privileged → relatively high graft survival.
Keratoplasty: penetrating (full-thickness) or lamellar (DALK anterior, DSEK/DMEK endothelial); promote eye donation to address donor shortage.
📚
SOURCES: Khurana's Comprehensive Ophthalmology.
THE CONCEPT
Ophthalmia neonatorum is conjunctivitis in the newborn (within the first 28 days of life), usually acquired during birth from the mother's genital tract. It is a preventable cause of childhood blindness and, in its gonococcal form, a medical emergency.
CAUSES
Neisseria gonorrhoeae — hyperacute (onset 1–3 days), with profuse purulent discharge, which can rapidly perforate the cornea and blind the eye.
Chlamydia trachomatis — the commonest cause (onset 5–14 days), with mucopurulent discharge (and a risk of pneumonia).
Other bacteria, and chemical conjunctivitis (from silver nitrate).
MANAGEMENT & PREVENTION
Treatment is urgent: gonococcal → systemic and topical antibiotics (ceftriaxone) with saline lavage; chlamydial → systemic erythromycin (also treating any pneumonia); and treatment of the parents. Prevention is by Credé's prophylaxis (silver nitrate or antibiotic eye drops at birth), antenatal screening/treatment of maternal STIs, and clean delivery.
A NOTE ON WHY THE GONOCOCCAL FORM IS FEARED
The reason ophthalmia neonatorum is treated so urgently is the gonococcal form, which is a true ocular emergency in the newborn. Unlike most neonatal conjunctivitis, Neisseria gonorrhoeae can penetrate an intact cornea and cause rapid ulceration and perforation within a day or two, blinding the eye before effective treatment is given. This is why any newborn with a hyperacute, profusely purulent conjunctivitis in the first days of life is assumed to be gonococcal until proven otherwise and treated immediately with systemic antibiotics, and why prophylaxis at birth and antenatal screening/treatment of maternal infection are emphasised — a small preventive effort that averts a devastating, lifelong disability.
THE BOTTOM LINE
Ophthalmia neonatorum is neonatal conjunctivitis from the birth canal whose gonococcal form can rapidly blind, so it is treated urgently and, above all, prevented by birth prophylaxis and maternal screening.
A further preventive point is that ophthalmia neonatorum sits at the interface of maternal and child health: because the organisms come from the mother's genital tract, the most effective prevention is the antenatal detection and treatment of maternal sexually transmitted infections, combined with clean delivery and birth prophylaxis — so preventing neonatal blindness begins with the care of the mother during pregnancy.
🔑
KEY POINTS TO REMEMBER
Ophthalmia neonatorum = conjunctivitis in the first 28 days, from the maternal genital tract; preventable cause of childhood blindness.
Prevent: Credé's prophylaxis (silver nitrate/antibiotic drops at birth), antenatal STI screening/treatment, clean delivery.
📚
SOURCES: Khurana's Comprehensive Ophthalmology.
THE CONCEPT
Low vision is visual impairment that cannot be corrected by glasses, surgery or medicine and that interferes with daily activities, but where some useful residual vision remains. Rehabilitation aims to maximise the use of that residual vision and restore independence — an essential service for the many people with irreversible eye disease.
LOW VISION AIDS
Optical — magnifiers, telescopes and high-plus spectacles.
Non-optical — large print, high contrast, good lighting and reading stands.
Electronic — CCTV/video magnifiers, screen readers and smartphone apps.
BROADER REHABILITATION
Comprehensive rehabilitation also includes orientation and mobility training, Braille, educational and vocational support, and counselling. It is particularly important for irreversible conditions such as ARMD, retinitis pigmentosa, glaucoma and diabetic retinopathy, and forms a key part of tertiary prevention within comprehensive eye care.
A NOTE ON ITS PLACE IN COMPREHENSIVE EYE CARE
Low-vision rehabilitation is an important reminder that eye care does not end when a condition becomes untreatable. For the large and growing number of people with irreversible visual loss from ARMD, glaucoma, diabetic retinopathy and retinitis pigmentosa, rehabilitation is what preserves independence, education, employment and quality of life, making use of the residual vision they still have. As the world's population ages and these chronic conditions become commoner, low-vision services and rehabilitation form an increasingly essential component of comprehensive eye care and of tertiary prevention, complementing — rather than being replaced by — the medical and surgical treatment of avoidable blindness.
THE BOTTOM LINE
Low-vision aids and rehabilitation maximise the residual vision and independence of people with irreversible visual loss, forming an essential, growing part of comprehensive eye care.
It is also worth emphasising that effective low-vision care depends on proper assessment of the residual vision and the individual's specific goals (reading, mobility, work or study), so that the right combination of aids and training is chosen; a well-matched magnifier or lighting change, together with training in how to use remaining vision, can restore functions that the person had given up as lost.
🔑
KEY POINTS TO REMEMBER
Low vision = uncorrectable visual impairment affecting daily life, but with useful residual vision; rehabilitation maximises its use and independence.
Plus orientation/mobility training, Braille, education/vocational support, counselling.
Important for irreversible disease (ARMD, RP, glaucoma, diabetic retinopathy); a key tertiary-prevention service.
📚
SOURCES: Khurana's Comprehensive Ophthalmology.
THE CONCEPT
Onchocerciasis ('river blindness') is a parasitic cause of blindness caused by the filarial worm Onchocerca volvulus, transmitted by the bite of the blackfly (Simulium), which breeds in fast-flowing rivers — hence the name. It is endemic in sub-Saharan Africa (and parts of Latin America/Yemen) and is a VISION 2020 priority disease.
FEATURES
The adult worms live in subcutaneous nodules, and their microfilariae migrate through the tissues — including the eye, where they cause sclerosing keratitis, iridocyclitis, chorioretinitis and optic atrophy, leading to blindness. There is also intense itching and skin disease (onchodermatitis). Historically it has been a leading infectious cause of blindness after trachoma.
DIAGNOSIS & CONTROL
Diagnosis is by skin snip (microfilariae), slit-lamp examination (microfilariae visible in the anterior chamber) and nodule biopsy. Control is by ivermectin (mass drug administration, which kills the microfilariae) and vector (blackfly) control; community-directed treatment programmes have dramatically reduced the disease.
A NOTE ON A CONTROL SUCCESS STORY
Onchocerciasis is worth knowing as one of the great success stories of community-directed control. The introduction of ivermectin, donated for mass drug administration and delivered by communities themselves once or twice a year, has — alongside vector (blackfly) control — dramatically reduced both the ocular and skin disease across large areas of Africa and the Americas, with some regions approaching elimination. It illustrates the core community-ophthalmology principle that a simple, safe, periodic intervention delivered at population scale can control a blinding disease, and it is precisely this model — a priority disease, a cheap effective treatment, and community-based delivery — that underlies its inclusion among the VISION 2020 target diseases.
THE BOTTOM LINE
Onchocerciasis (river blindness) is a blackfly-borne filarial cause of blindness controlled successfully by community-based ivermectin mass drug administration and vector control — a VISION 2020 priority disease.
Finally, it is worth appreciating that onchocercal eye disease develops slowly, over years of repeated microfilarial invasion, so that regular ivermectin treatment — which kills the microfilariae but not the long-lived adult worms — must be continued periodically over a prolonged period to prevent the accumulation of ocular damage; this need for sustained, repeated community treatment is central to the design of onchocerciasis-control programmes.
🔑
KEY POINTS TO REMEMBER
Onchocerciasis (river blindness) = Onchocerca volvulus, transmitted by the blackfly (Simulium) that breeds in fast rivers; endemic in sub-Saharan Africa.
Microfilariae reach the eye → sclerosing keratitis, iridocyclitis, chorioretinitis, optic atrophy → blindness; plus itching and skin disease + subcutaneous nodules.
Diagnose by skin snip (microfilariae), slit-lamp (microfilariae in AC), nodule biopsy.
Control by ivermectin mass drug administration (kills microfilariae) + blackfly vector control; a VISION 2020 priority disease.
📚
SOURCES: Khurana's Comprehensive Ophthalmology; Park's Textbook of Preventive & Social Medicine.